非小细胞肺癌的 EGFR-TKI 新辅助疗法

IF 9.6 1区医学 Q1 ONCOLOGY

Cancer treatment reviews Pub Date : 2024-03-27 DOI:10.1016/j.ctrv.2024.102724

Christopher Grant , Misako Nagasaka

{"title":"非小细胞肺癌的 EGFR-TKI 新辅助疗法","authors":"Christopher Grant , Misako Nagasaka","doi":"10.1016/j.ctrv.2024.102724","DOIUrl":null,"url":null,"abstract":"<div><p>Non-small cell lung cancer (NSCLC) stages I-III are predominantly treated with surgery and combination immunotherapy and chemotherapy. A majority of these studies excluded patients with <em>EGFR</em> and <em>ALK</em> alterations. There are several completed and ongoing trials evaluating neoadjuvant treatment with <em>EGFR-TKI</em> monotherapy, combination therapy with chemotherapy, and combination therapy with immunotherapy. Here, we review completed clinical trials and discuss current ongoing trials’ potential benefits, challenges, and future directions in the field.</p></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":null,"pages":null},"PeriodicalIF":9.6000,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0305737224000513/pdfft?md5=a916c4b1247f0df2d57685d15c548e76&pid=1-s2.0-S0305737224000513-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer\",\"authors\":\"Christopher Grant , Misako Nagasaka\",\"doi\":\"10.1016/j.ctrv.2024.102724\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Non-small cell lung cancer (NSCLC) stages I-III are predominantly treated with surgery and combination immunotherapy and chemotherapy. A majority of these studies excluded patients with <em>EGFR</em> and <em>ALK</em> alterations. There are several completed and ongoing trials evaluating neoadjuvant treatment with <em>EGFR-TKI</em> monotherapy, combination therapy with chemotherapy, and combination therapy with immunotherapy. Here, we review completed clinical trials and discuss current ongoing trials’ potential benefits, challenges, and future directions in the field.</p></div>\",\"PeriodicalId\":9537,\"journal\":{\"name\":\"Cancer treatment reviews\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":9.6000,\"publicationDate\":\"2024-03-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0305737224000513/pdfft?md5=a916c4b1247f0df2d57685d15c548e76&pid=1-s2.0-S0305737224000513-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer treatment reviews\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0305737224000513\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0305737224000513","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

非小细胞肺癌（NSCLC）I-III 期主要采用手术和免疫化疗联合疗法进行治疗。这些研究大多排除了表皮生长因子受体（EGFR）和ALK改变的患者。有几项已完成和正在进行的试验评估了 EGFR-TKI 单药、化疗联合疗法以及免疫疗法联合疗法的新辅助治疗。在此，我们回顾了已完成的临床试验，并讨论了目前正在进行的试验的潜在益处、挑战以及该领域的未来发展方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer

Non-small cell lung cancer (NSCLC) stages I-III are predominantly treated with surgery and combination immunotherapy and chemotherapy. A majority of these studies excluded patients with EGFR and ALK alterations. There are several completed and ongoing trials evaluating neoadjuvant treatment with EGFR-TKI monotherapy, combination therapy with chemotherapy, and combination therapy with immunotherapy. Here, we review completed clinical trials and discuss current ongoing trials’ potential benefits, challenges, and future directions in the field.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer treatment reviews 医学-肿瘤学

CiteScore

21.40

自引率

0.80%

发文量

109

审稿时长

13 days

期刊介绍： Cancer Treatment Reviews Journal Overview: International journal focused on developments in cancer treatment research Publishes state-of-the-art, authoritative reviews to keep clinicians and researchers informed Regular Sections in Each Issue: Comments on Controversy Tumor Reviews Anti-tumor Treatments New Drugs Complications of Treatment General and Supportive Care Laboratory/Clinic Interface Submission and Editorial System: Online submission and editorial system for Cancer Treatment Reviews